B

Biomm
BIOM3

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
R$1.32B
EV
R$1.32B
Shares Outstanding
126.84M
Beta
0.74

Wall Street View

Analyst Rating
NOT_AVAILABLE
Analyst Target Price
-
P/E 2025E
-
P/Revenue 2025E
-

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Biomm S.A.

gainify

B

Biomm S.A.

BIOM3

Biomm S.A. operates as a biotechnology company in Brazil. The company offers AFREZZA, a human insulin inhalation powder; GHEMAXAN, an enoxaparina sodica; GLARGILIN, a glargine insulin; WOSULIN R, a human insulin; WOSULIN N, an isophane insulin; HERZUMA, a trastuzumab;...

Sector

Healthcare

Industry

Biotechnology

CEO

Marchezini, Heraldo

Employees

130

IPO Date

2000-01-11

Headquarters

705 – Lagoa dos Ingleses, Avenida Regent, Alphaville, Nova Lima, Minas Gerais, 34018-000, Brazil

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on Threads
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.